False
By Jessica Allerton, James Strachan
August 18, 2026
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
10 min read
August 14, 2026
Why effective study training depends on relevance, timing, and oversight.
0 min read
August 3, 2026
A previously undisclosed death in China raises questions about gene-editing oversight, deramiocel meets its Phase 3 Duchenne endpoint, and researchers identify a source of CAR NK dysfunction
4 min read
By James Strachan, Kathryn Wighton
July 15, 2026
Daphne Smyth of Veristat on the rise of Chinese biopharma, regulatory realities, and what comes next
8 min read
July 13, 2026
Selected companies will receive earlier FDA engagement to support new US drug manufacturing facilities across small molecules, biologics, sterile injectables, and advanced therapies
2 min read
July 2, 2026
How UCB is improving traceability, audit readiness, and visibility.
1 min read
By Laurent Claisse
June 30, 2026
Late-stage CMC setbacks often begin with early QC decisions that shape cell and gene therapy timelines, costs, and regulatory outcomes
7 min read
June 30, 2026
A special collection of recent stories exploring oral dose innovation, API stability, nitrosamine testing, and the evolving science of small molecule medicines
1 min read
June 29, 2026
How connected quality systems can help growing biotechs remain agile.
0 min read
June 25, 2026
IBTV speaks with industry leaders at ARM’s Meeting on the Med 2026 to explore what recent clinical, regulatory, and commercial milestones reveal about the next phase of cell and gene therapy
False